Agios Pharmaceuticals Appoints Paul J. Clancy to Its Board of Directors

Agios Pharmaceuticals Appoints Paul J. Clancy to Its Board of Directors

September 26, 2013

CAMBRIDGE, Mass., Sep 26, 2013 (BUSINESS WIRE) -- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), today announced the addition of Paul J. Clancy, executive vice president and chief financial officer at Biogen Idec, to the company's board of directors.

Novomer Catalytic Process Using Waste CO2 and Shale Gas Targets $20 Billion Market and up to 110% Carbon Footprint Reduction

Novomer Catalytic Process Using Waste CO2 and Shale Gas Targets $20 Billion Market and up to 110% Carbon Footprint Reduction

September 24, 2013

DoE Grant and New Partnership Fuel Potential to Rejuvenate US Global Chemical Market Leadership; "Drop in" Chemical Market Replacements to Reach Commercial Scale in 2017

Visterra Named One of the “Fierce 15” Leading Biotech Companies of 2013

Visterra Named One of the “Fierce 15” Leading Biotech Companies of 2013

September 24, 2013

CAMBRIDGE, Mass., Sep 24, 2013 (BUSINESS WIRE) -- Visterra, Inc., developer of novel therapeutics to prevent and treat major infectious diseases, today announced that FierceBiotech has named it as one of 2013's "Fierce 15," designating Visterra as one of the most promising private biotechnology companies in the industry. This is FierceBiotech's eleventh annual "Fierce 15" selection.

Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013

Moderna Therapeutics Named a "Fierce 15" Biotech Company for 2013

September 24, 2013

CAMBRIDGE, Mass., Sept. 24, 2013 /PRNewswire/ -- Moderna Therapeutics, the pioneering company developing messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that FierceBiotech has named Moderna as one of 2013's Fierce 15.

BG Medicine, Inc. Welcomes Galectin-3 Clinical Research Data From the PROTECT Study Conducted at Massachusetts General Hospital Demonstrating Predictive Value of Adverse Outcomes in Heart Failure Patients

BG Medicine, Inc. Welcomes Galectin-3 Clinical Research Data From the PROTECT Study Conducted at Massachusetts General Hospital Demonstrating Predictive Value of Adverse Outcomes in Heart Failure Patients

September 23, 2013

WALTHAM, Mass., Sept. 23, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today the publication of the results of a clinical research study conducted at the Massachusetts General Hospital (MGH) that provide further evidence that elevated levels of galectin-3 are predictive of adverse outcomes in chronic heart failure patients and suggest that the prognostic value of this non-invasive biomarker may be enhanced when serial measurements are made over time.

Agios Pharmaceuticals Enrolls First Patient in Phase 1 Study of AG-221 in Advanced Hematologic Malignancies with an IDH2 Mutation

Agios Pharmaceuticals Enrolls First Patient in Phase 1 Study of AG-221 in Advanced Hematologic Malignancies with an IDH2 Mutation

September 23, 2013

-- First-in-class Clinical Program Targets Cancer Metabolism in Genetically Defined Patient Population --

Eleven Biotherapeutics Presents Positive Clinical Data on EBI‐005, a Targeted Protein Therapeutic for

Eleven Biotherapeutics Presents Positive Clinical Data on EBI‐005, a Targeted Protein Therapeutic for

September 20, 2013

Demonstrated Dual Action in Treating both the Signs and Symptoms of Dry Eye
Eleven to Advance EBI-005 into Pivotal Clinical Study for Dry Eye Disease

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

BIND Therapeutics Announces Pricing of Initial Public Offering

BIND Therapeutics Announces Pricing of Initial Public Offering

September 19, 2013

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called Accurins™, announced today the pricing of its initial public offering of 4,700,000 shares of its common stock at a public offering price of $15.00 per share, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Select Market under the ticker symbol "BIND" on September 20, 2013.

Tangent Medical Wins Gold & Silver Stevie® Awards

Tangent Medical Wins Gold & Silver Stevie® Awards

September 18, 2013

Company Recognized for Best New Product or Service for Health & Pharmaceuticals and Tech Innovation of the Year

Acceleron Announces Pricing of Initial Public Offering

Acceleron Announces Pricing of Initial Public Offering

September 18, 2013

Cambridge, Mass. – September 18, 2013 - Acceleron Pharma, Inc. today announced the pricing of its initial public offering of 5,580,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts. In addition, Acceleron has granted the underwriters a 30-day option to purchase up to an additional 837,000 shares of common stock at the public offering price, less underwriting discounts.